To meet the needs of different patients, we have developed a range of specialised catheter lock solutions. TauroLock™-HEP100 is an option for those who have previously used heparin as an anti-occlusive agent.
Indication and effect
TauroLock™-HEP100 has been approved for instillation in all central-venous access systems. This lock solution prevents the formation of a bacterial biofilm and thereby protects patients against catheter-related infections. At the same time, it ensures a high patency rate. We recommend TauroLock-HEP100 for CVCs in oncology and parenteral nutrition.
TauroLock™-Hep100 contains three active ingredients:
- heparin (100 units per ml)
- citrate (4 %)
Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida). Heparin and citrate both help to prevent occlusions within the catheter.
In-between treatment sessions, TauroLock™-HEP100 is instilled into the saline-flushed access system. Please note that medical staff must check the filling volume of the respective catheter or port system.
Taurolidine-based lock solutions such as TauroLock™-HEP100 are recommended in national and international guidelines. For patients suffering from heparin-induced thrombocytopenia (HIT), we offer two heparin-free alternatives:
Patients diagnosed with HIT should not use TauroLock™-HEP100 for their vascular access system (VAD). Instead, we recommend TauroLock™ and/or TauroLock™-U25.000.
TauroLock™ is not suitable for patients who:
- have displayed a hypersensitive reaction to citrate or taurolidine
- are taking medication that interferes with either citrate, heparin, or taurolidine
TauroLock™-HEP100 must be aspirated before the next treatment.
TauroLock™-HEP100 is available in ampoules of 3 ml (single dose,10 ampoules per box).
Storage & transport
TauroLock™-HEP100 must be stored at temperatures between 15 °C and 30 °C. While ampoules are designed for single use, vials remain usable within a period of 48 hours. Please note that you must not freeze TauroLock™-HEP100 under any circumstances.
More about TauroLock™-HEP100
National guideline recommendations, e.g. GPOH 2018:
“Lock solutions containing taurolidine are recommended for the prevention of CVAD-associated infections.”
21.4 Taurolidine for the Prophylaxis against CVAD-related Infection
Lock solutions containing Taurolidine are recommended for the prevention of CVAD-associated Infections (scientific evidence Cat. IB, problem: reimbursement in outpatient care).
Taurolidine containing lock solutions are also recommended for paediatric-oncologic patients on cyclized (home-)parenteral nutrition if an infusion-free interval of at least 4 hours is available (Cat. IB for patients on home-parenteral nutrition).
23.6.3 Taurolidine-Lock for adjuvant therapy
Taurolidine (e.g. 1.35% Taurolidine, 4% Citrate) can be used as adjuvant measure during systemic treatment with antibiotics (Cat. II). The minimal dwell time in the catheter lumen is 4 hours.
For personal inquiries, feel free to contact us via phone or email.
Our international distributors based in more than 50 countries will answer your requests ASAP.